Format

Send to

Choose Destination
Hematol Oncol. 2018 Aug 16. doi: 10.1002/hon.2536. [Epub ahead of print]

Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals.

Author information

1
Division of Hematology, Department of Internal Medicine, Ospedale degli Infermi, Biella, Italy.
2
IOSI Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.
3
Foundation for the Institute of Oncology Research (IOR), Bellinzona, Switzerland.
4
Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont and AOU Maggiore della Carità, Novara, Italy.
5
Infectious Disease Service, Lausanne University Hospital, Lausanne, Switzerland.
6
Division of Infectious Diseases and Hospital Epidemiology, University Hospital, Zurich, University of Zurich, Zurich, Switzerland.
7
Division of Infectious Diseases, University Hospital, Basel, Switzerland.
8
Department of Infectious Diseases, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
9
Department of Medical Oncology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland.
10
Division of Infectious Diseases, Cantonal Hospital, St Gallen, St Gallen, Switzerland.
11
Swiss HIV Cohort Study Data Center, University Hospital and University of Zurich, Zurich, Switzerland.
12
Institute of Pathology, University of Basel, Basel, Switzerland.
13
Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland.
14
Dalle Molle Institute for Artificial Intelligence (IDSIA), Manno, Switzerland.
15
SIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
16
Division of Infectious Diseases, Ospedale Regionale di Lugano, Lugano, Switzerland.

Abstract

The prognostic factors and outcome of 58 acquired immunodeficiency syndrome-related diffuse large B-cell lymphoma (AR-DLBCL) patients from the Swiss HIV Cohort Study, diagnosed from 2004 to 2011, were compared with those of 326 immunocompetent (IC)-DLBCL from the Hematology Division of the Amedeo Avogadro University (Italy) and the Oncology Institute of Southern Switzerland. Median follow-up was 6 years; 5-year overall survival (OS) was 68% (95% CI: 63%-73%) in IC-DLBCL and 63% (95% CI: 49%-75%) in AR-DLBCL (P = .220). The acquired immunodeficiency syndrome-related lymphoma international prognostic index predicted OS in AR-DLBCL. Among 148 patients younger than 61 years (40 AR-DLBCL and 108 IC-DLBCL) treated with RCHOP/RCHOP-like regimens, 20 IC-DLBCL and 9 AR-DLBCL patients died and OS was not significantly different. A higher proportion of early deaths occurred in the AR-DLBCL: indeed, 1-year OS was 94% (95% CI: 87%-97%) in IC-DLBCL and 82% (95% CI: 66%-91%) in AR-DLBCL patients. After rituximab and active antiretroviral therapy introduction, AR-DLBCL and IC-DLBCL patients treated with curative intent have similar long-term survival.

KEYWORDS:

AIDS; HIV infection; diffuse large B-cell lymphoma; prognostic factors; therapy

PMID:
30113708
DOI:
10.1002/hon.2536

Supplemental Content

Loading ...
Support Center